MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/7/2007 12:44:11 AM
	of 1826

MGI Pharma "buy," estimates raised Wednesday, June 06, 2007 6:59:31 AM ET Lazard Capital Markets NEW YORK, June 6 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on MGI Pharma (MOGN.NAS), while raising their estimates for the company. The target price is set to $30. In a research note published yesterday, the analysts mention that the company’s new data on Dacogen in AML in the elderly indicates substantial safety improvements and efficacy over the currently available treatments. The Phase II data on Irofulven in prostate cancer also indicates a trend towards survival, the analysts say. Future catalysts for the company’s share price include the Dacogen Phase III data in MDS and AML in 2008 and the Aquavan NDA filing in 3Q07, Lazard Capital adds. The EPS estimate for 2007 has been raised from $0.71 to $0.72.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next